<DOC>
	<DOC>NCT00693524</DOC>
	<brief_summary>Study to evaluate the benefits and any risks of the delayed administration of tacrolimus in a combined regimen of mycophenolate mofetil and monoclonal anti-IL2R antibodies (daclizumab), in comparison with a standard steroid + tacrolimus double drug regimen</brief_summary>
	<brief_title>Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient is undergoing orthotopic liver allograft transplantation. This includes partial organ transplantation. Age of donor between 5 and 65 years Patient has previously received or is receiving an organ transplant (including liver retransplantation) Recipient of an auxiliary graft or in which a bioartificial liver has been used Patient is receiving a living related liver transplantation Patient is requiring steroids as well as chemotherapy prior to transplantation Patient having any previous history of neoplastic disease of any type (including leukaemia). However, patients with primary liver carcinoma can be included if they meet the following criteria: &gt; 3 nodes No node larger than 5 cm No metastases No vascular invasion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>liver allograft transplantation</keyword>
	<keyword>sequential therapy</keyword>
	<keyword>tacrolimus</keyword>
</DOC>